168 related articles for article (PubMed ID: 17102906)
1. Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival.
Sugita Y; Takase Y; Mori D; Tokunaga O; Nakashima A; Shigemori M
J Neurooncol; 2007 May; 82(3):249-56. PubMed ID: 17102906
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody.
Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Yamada T; Hanaoka N; Inui K; Wada H
Clin Cancer Res; 2001 Nov; 7(11):3410-5. PubMed ID: 11705856
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver.
Ho JW; Poon RT; Sun CK; Xue WC; Fan ST
World J Gastroenterol; 2005 Jan; 11(2):176-81. PubMed ID: 15633211
[TBL] [Abstract][Full Text] [Related]
4. Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: comparison between CD105 and CD34 as a marker of angiogenesis.
Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Ishikawa S; Wada H
Lung Cancer; 2003 Mar; 39(3):289-96. PubMed ID: 12609567
[TBL] [Abstract][Full Text] [Related]
5. Endoglin (CD 105) as a potential prognostic factor in neuroblastoma.
Ćavar S; Jelašić D; Seiwerth S; Milošević M; Hutinec Z; Mišić M
Pediatr Blood Cancer; 2015 May; 62(5):770-5. PubMed ID: 25683142
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.
Netto GC; Bleil CB; Hilbig A; Coutinho LM
Neuropathology; 2008 Feb; 28(1):17-23. PubMed ID: 18181830
[TBL] [Abstract][Full Text] [Related]
7. Microvessel density assessment in benign and malignant endometrial changes.
Czekierdowski A; Czekierdowska S; Czuba B; Cnota W; Sodowski K; Kotarski J; Zwirska-Korczala K
J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():45-51. PubMed ID: 18955753
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma.
Di Paolo V; Russo I; Boldrini R; Ravà L; Pezzullo M; Benedetti MC; Galardi A; Colletti M; Rota R; Orlando D; Crocoli A; Peinado H; Milano GM; Di Giannatale A
BMC Cancer; 2018 Jan; 18(1):31. PubMed ID: 29304781
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions.
Ding S; Li C; Lin S; Yang Y; Liu D; Han Y; Zhang Y; Li L; Zhou L; Kumar S
Hum Pathol; 2006 Jul; 37(7):861-6. PubMed ID: 16784986
[TBL] [Abstract][Full Text] [Related]
10. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas.
Barresi V; Cerasoli S; Vitarelli E; Tuccari G
Acta Neuropathol; 2007 Aug; 114(2):147-56. PubMed ID: 17594108
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD34 and CD105 as markers for angiogenesis in oral vascular malformations and pyogenic granulomas.
Vasconcelos MG; Alves PM; Vasconcelos RG; da Silveira ÉJD; Medeiros AMC; de Queiroz LMG
Eur Arch Otorhinolaryngol; 2011 Aug; 268(8):1213-1217. PubMed ID: 21221622
[TBL] [Abstract][Full Text] [Related]
12. BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma.
Ratajczak P; Leboeuf C; Wang L; Brière J; Loisel-Ferreira I; Thiéblemont C; Zhao WL; Janin A
Mod Pathol; 2012 Jun; 25(6):805-14. PubMed ID: 22322190
[TBL] [Abstract][Full Text] [Related]
13. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
Rubatt JM; Darcy KM; Hutson A; Bean SM; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
[TBL] [Abstract][Full Text] [Related]
14. Microvessel Landscape Assessment in Pancreatic Ductal Adenocarcinoma: Unclear Value of Targeting Endoglin (CD105) as Prognostic Factor of Clinical Outcome.
Lytras D; Leontara V; Kefala M; Foukas PG; Giannakou N; Pouliakis A; Dervenis C; Panayiotides IG; Karakitsos P
Pancreas; 2015 Jan; 44(1):87-92. PubMed ID: 25058886
[TBL] [Abstract][Full Text] [Related]
15. Neoangiogenesis in laryngeal carcinoma: angiogenin and CD105 expression is related to carcinoma recurrence rate and disease-free survival.
Marioni G; Marino F; Blandamura S; D'Alessandro E; Giacomelli L; Guzzardo V; Lionello M; De Filippis C; Staffieri A
Histopathology; 2010 Oct; 57(4):535-43. PubMed ID: 20955379
[TBL] [Abstract][Full Text] [Related]
16. Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF.
Yao Y; Pan Y; Chen J; Sun X; Qiu Y; Ding Y
Ann Clin Lab Sci; 2007; 37(1):39-48. PubMed ID: 17311868
[TBL] [Abstract][Full Text] [Related]
17. Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers.
Minhajat R; Mori D; Yamasaki F; Sugita Y; Satoh T; Tokunaga O
Virchows Arch; 2006 Feb; 448(2):127-34. PubMed ID: 16177881
[TBL] [Abstract][Full Text] [Related]
18. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
Basilio-de-Oliveira RP; Pannain VL
World J Gastroenterol; 2015 Jun; 21(22):6924-30. PubMed ID: 26078569
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody.
Yao Y; Kubota T; Takeuchi H; Sato K
Neuropathology; 2005 Sep; 25(3):201-6. PubMed ID: 16193836
[TBL] [Abstract][Full Text] [Related]
20. Endoglin (CD105) is a useful marker for evaluating microvessel density and predicting prognosis in esophageal squamous cell carcinoma.
Sakurai T; Okumura H; Matsumoto M; Uchikado Y; Owaki T; Kita Y; Setoyama T; Omoto I; Kijima Y; Ishigami S; Natsugoe S
Anticancer Res; 2014 Jul; 34(7):3431-8. PubMed ID: 24982351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
